Evaluation of the Inflammation-Based mGPS as a Prognostic and Predictive Biomarker in Patients With Metastatic Colorectal Cancer Receiving First-Line Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)
ESMO Open 2024 May 13;9(5)103374, M Boukovala, DP Modest, I Ricard, L Fischer von Weikersthal, T Decker, U Vehling-Kaiser, J Uhlig, M Schenk, J Freiberg-Richter, B Peuser, C Denzlinger, C Peveling Genannt Reddemann, U Graeven, G Schuch, I Schwaner, K Heinrich, J Neumann, A Jung, S Held, S Stintzing, V Heinemann, M MichlFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.